Board of Scientific Counselors Meeting, National Institute for Occupational Safety and Health (NIOSH), 37102 [05-12689]

Download as PDF 37102 Federal Register / Vol. 70, No. 123 / Tuesday, June 28, 2005 / Notices pertaining to announcements of meetings and other committee management activities for both CDC and the Agency for Toxic Substances and Disease Registry. DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention Dated: June 22, 2005. Alvin Hall, Director, Management Analysis and Services Office, Centers for Disease Control and Prevention. [FR Doc. 05–12689 Filed 6–27–05; 8:45 am] Board of Scientific Counselors Meeting, National Institute for Occupational Safety and Health (NIOSH) In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the following committee meeting: Name: Board of Scientific Counselors (BSC), NIOSH. Time and Date: 10 a.m.–3:30 p.m., July 21, 2005. Place: National Institute for Occupational Safety and Health, Robert A. Taft Laboratories, 4676 Columbia Parkway, Cincinnati, Ohio 45226. Status: Open to the public, limited only by the space available. The meeting room accommodates approximately 50 people. Visiting members of the public must present valid identification (U.S. Federal ID, State Driver’s License, or other State-sanctioned ID) for entry to Taft Laboratories and must be escorted by facility staff at all times while inside the facility. Purpose: The Secretary, Department of Health and Human Services; the Assistant Secretary for Health; and by delegation the Director, Centers for Disease Control and Prevention, are authorized under Sections 301 and 308 of the Public Health Service Act to conduct directly or by grants or contracts, research, experiments, and demonstrations relating to occupational safety and health and to mine health. The Board of Scientific Counselors shall provide guidance to the Director, NIOSH, on research and preventions programs. Specifically, the Board shall provide guidance on the Institute’s research activities related to developing and evaluating hypotheses, systematically documenting findings and disseminating results. The Board shall evaluate the degree to which the activities of NIOSH: (1) Conform to appropriate scientific standards, (2) address current, relevant needs, and (3) produce intended results. Matters To be Discussed: Agenda items include a report from the Director of NIOSH; progress reports by BSC working groups on the National Occupational Research Agenda and the health hazard evaluation program, NIOSH emergency/terrorism preparedness, a tour of the Taft Laboratories, and closing remarks. Agenda items are subject to change as priorities dictate. Contact Person for More Information: Roger Rosa, Executive Secretary, BSC, NIOSH, CDC, 200 Independence Avenue, SW., Room 715H, Washington, DC 20201, telephone (202) 205–7856, fax (202) 260– 4464. The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register notices VerDate jul<14>2003 16:46 Jun 27, 2005 Jkt 205001 BILLING CODE 4163–18–P Dated: June 20, 2005. Jeffrey Shuren, Assistant Commissioner for Policy. [FR Doc. 05–12763 Filed 6–27–05; 8:45 am] BILLING CODE 4160–01–S DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. 2005D–0240] DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. 2001D–0262] (formerly Docket No. 01–0262) Draft ‘‘Guidance for Food and Drug Administration Reviewers: Premarket Notification Submissions for Automated Testing Instruments Used in Blood Establishments;’’ Withdrawal of Guidance AGENCY: Food and Drug Administration, HHS. ACTION: Notice; withdrawal. SUMMARY: The Food and Drug Administration (FDA) is announcing the withdrawal of a draft guidance that was issued on August 3, 2001. DATES: June 28, 2005. FOR FURTHER INFORMATION CONTACT: Paul E. Levine, Jr., Center for Biologics Evaluation and Research (HFM–17), Food and Drug Administration, 1401 Rockville Pike, suite 200N, Rockville, MD 20852–1448, 301–827–6210. SUPPLEMENTARY INFORMATION: In a notice published in the Federal Register of August 3, 2001 (66 FR 40708), FDA announced the availability of a draft document entitled ‘‘Guidance for FDA Reviewers: Premarket Notification Submissions for Automated Testing Instruments Used in Blood Establishments.’’ This draft guidance is being withdrawn because it no longer reflects the following: (1) All of the information FDA reviewers should expect to be included in a premarket notification submitted to the Center for Biologics Evaluation and Research for such devices and (2) the recommended approach FDA reviewers should take in reviewing premarket submissions for automated instruments testing used in blood establishments. In the future, FDA may issue for public comment draft special control guidances on instrumentation for blood borne pathogen donor screening and immunohematology testing. PO 00000 Frm 00028 Fmt 4703 Sfmt 4703 Draft Guidance for Industry on Gingivitis: Development and Evaluation of Drugs for Treatment or Prevention; Availability AGENCY: Food and Drug Administration, HHS. ACTION: Notice. SUMMARY: The Food and Drug Administration (FDA) is announcing the availability of a draft guidance for industry entitled ‘‘Gingivitis: Development and Evaluation of Drugs for Treatment or Prevention.’’ The draft guidance is intended to assist sponsors in developing clinical trials for drug products that treat or prevent gingivitis. It addresses specific protocol design elements as well as general concerns about drugs for this indication. DATES: Submit written or electronic comments on the draft guidance by August 29, 2005. General comments on agency guidance documents are welcome at any time. ADDRESSES: Submit written requests for single copies of the draft guidance to the Division of Drug Information (HFD– 240), Center for Drug Evaluation and Research, Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857. Send one selfaddressed adhesive label to assist that office in processing your requests. Submit written comments on the draft guidance to the Division of Dockets Management (HFA–305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. Submit electronic comments to https:// www.fda.gov/dockets/ecomments. See the SUPPLEMENTARY INFORMATION section for electronic access to the draft guidance document. FOR FURTHER INFORMATION CONTACT: Frederick Hyman, Center for Drug Evaluation and Research (HFD–540), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827–2020. SUPPLEMENTARY INFORMATION: I. Background FDA is announcing the availability of a draft guidance for industry entitled E:\FR\FM\28JNN1.SGM 28JNN1

Agencies

[Federal Register Volume 70, Number 123 (Tuesday, June 28, 2005)]
[Notices]
[Page 37102]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-12689]



[[Page 37102]]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention


Board of Scientific Counselors Meeting, National Institute for 
Occupational Safety and Health (NIOSH)

    In accordance with section 10(a)(2) of the Federal Advisory 
Committee Act (Pub. L. 92-463), the Centers for Disease Control and 
Prevention (CDC) announces the following committee meeting:

    Name: Board of Scientific Counselors (BSC), NIOSH.
    Time and Date: 10 a.m.-3:30 p.m., July 21, 2005.
    Place: National Institute for Occupational Safety and Health, 
Robert A. Taft Laboratories, 4676 Columbia Parkway, Cincinnati, Ohio 
45226.
    Status: Open to the public, limited only by the space available. 
The meeting room accommodates approximately 50 people. Visiting 
members of the public must present valid identification (U.S. 
Federal ID, State Driver's License, or other State-sanctioned ID) 
for entry to Taft Laboratories and must be escorted by facility 
staff at all times while inside the facility.
    Purpose: The Secretary, Department of Health and Human Services; 
the Assistant Secretary for Health; and by delegation the Director, 
Centers for Disease Control and Prevention, are authorized under 
Sections 301 and 308 of the Public Health Service Act to conduct 
directly or by grants or contracts, research, experiments, and 
demonstrations relating to occupational safety and health and to 
mine health. The Board of Scientific Counselors shall provide 
guidance to the Director, NIOSH, on research and preventions 
programs. Specifically, the Board shall provide guidance on the 
Institute's research activities related to developing and evaluating 
hypotheses, systematically documenting findings and disseminating 
results. The Board shall evaluate the degree to which the activities 
of NIOSH: (1) Conform to appropriate scientific standards, (2) 
address current, relevant needs, and (3) produce intended results.
    Matters To be Discussed: Agenda items include a report from the 
Director of NIOSH; progress reports by BSC working groups on the 
National Occupational Research Agenda and the health hazard 
evaluation program, NIOSH emergency/terrorism preparedness, a tour 
of the Taft Laboratories, and closing remarks.
    Agenda items are subject to change as priorities dictate.
    Contact Person for More Information: Roger Rosa, Executive 
Secretary, BSC, NIOSH, CDC, 200 Independence Avenue, SW., Room 715H, 
Washington, DC 20201, telephone (202) 205-7856, fax (202) 260-4464.
    The Director, Management Analysis and Services Office, has been 
delegated the authority to sign Federal Register notices pertaining 
to announcements of meetings and other committee management 
activities for both CDC and the Agency for Toxic Substances and 
Disease Registry.

    Dated: June 22, 2005.
Alvin Hall,
Director, Management Analysis and Services Office, Centers for Disease 
Control and Prevention.
[FR Doc. 05-12689 Filed 6-27-05; 8:45 am]
BILLING CODE 4163-18-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.